Literature DB >> 17124077

An update on therapy of primary central nervous system lymphoma.

Lisa M Deangelis1, Fabio M Iwamoto.   

Abstract

The most important advance in primary central nervous system (CNS) lymphoma treatment has been the convincing data that high-dose methotrexate-based chemotherapy regimens improve survival compared to historical controls treated with radiotherapy alone. However, the optimal treatment approach is still unclear and therapy can be associated with long-term neurotoxicity. Current research focuses on maximizing survival while minimizing neurologic sequelae.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124077     DOI: 10.1182/asheducation-2006.1.311

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  10 in total

1.  Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.

Authors:  Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

2.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

3.  Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.

Authors:  Zhan Wang; Qingyu Zhou; Gary D Kruh; James M Gallo
Journal:  Drug Metab Dispos       Date:  2011-08-12       Impact factor: 3.922

4.  Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.

Authors:  Samir Dalia; Peter Forsyth; Julio Chavez; Samantha Price; Bijal Shah; Celeste Bello; Lubomir Sokol; Edward Pan; Eduardo Sotomayor; Ji-Hyun Lee; Kate Fisher; Michael Jaglal
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

5.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

6.  Pathway analysis of primary central nervous system lymphoma.

Authors:  Han W Tun; David Personett; Karen A Baskerville; David M Menke; Kurt A Jaeckle; Pamela Kreinest; Brandy Edenfield; Abba C Zubair; Brian P O'Neill; Weil R Lai; Peter J Park; Michael McKinney
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

7.  Combined Modality Treatment Including Methotrexate-Based Chemotherapy For Primary CENTRAL Nervous System Lymphoma: A Single Institution Experience.

Authors:  Stefan Hohaus; Luciana Teofili; Mario Balducci; Stefania Manfrida; Angelo Pompucci; Francesco D'Alo'; Giuseppina Massini; Luigi Maria Larocca; Roberto Marra; Sergio Storti
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

8.  Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.

Authors:  Lore Marretta; H Stocker; D Drauz; M Mueller; A Masuhr; S Dieckmann; V Wong; A Koch; A Grueneisen; K Arastéh; R Weiss
Journal:  Eur J Med Res       Date:  2011-05-12       Impact factor: 2.175

9.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

10.  Primary intracranial lymphomas.

Authors:  Shagufta T Mufti; Saleh S Baeesa; Jaudah A Al-Maghrabi
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.